SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets nod to acquire portfolio of brands of Anglo-French Drugs & Industries

18 Jan 2022 Evaluate

Lupin has received an approval for the acquisition of a portfolio of brands (including all rights and interests associated with such products) of Anglo-French Drugs & Industries and its associates (subject to approval of their shareholders). The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the Vitamins, Minerals and Supplements category. The Board of Directors of the company at its meeting held on January 17, 2022, approved the same.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2476.10 77.40 (3.23%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: